Primary liver cancer originates from primary malignant tumor of liver, which is a highly prevalent and extremely harmful malignant tumor in China. In the past, liver cancer patients were often equal to a death sentence, with a survival period of 3-6 months. Nowadays, with the advancement of technology, liver cancer is no longer an incurable disease, some patients can be completely cured, and some patients can be treated to transform the malignant disease into chronic disease and obtain long-term survival. Comprehensive treatments include: surgery, minimally invasive laparoscopic surgery, liver radiofrequency, interventional therapy, and doxorubicin therapy. Surgical resection is still the main treatment for hepatocellular carcinoma, and is the most important measure to improve the cure rate and survival. For those diagnosed with no contraindication to surgery, whose general condition can tolerate general anesthesia, whose liver tumor can be removed, and whose remaining liver will not suffer from liver failure, early hepatectomy is preferred. For patients with severely impaired liver function, Child C should be considered for surgery only after a period of treatment to see if it can become Child A or B. It is very important to properly assess the patient’s liver function and the allowable amount of liver resection before surgery. Intraoperative control of bleeding and shortening the duration of hilar block or performing hemihepatic block are the main measures to reduce postoperative liver failure. Re-operation for recurrent tumors can still achieve a good survival rate. For tumors presenting at the margins of the liver, such as tumors in segments II, III, IV, V, and VI of the liver, or tumors that can be resected by right or left hemihepatectomy or left lateral hepatic segment, laparoscopic hepatectomy can also be considered, and this minimally invasive laparoscopic surgical approach has now become the standard procedure. Radiofrequency or microwave ablation is a minimally invasive tumor in situ treatment technique, with the help of imaging technology such as ultrasound or CT to locate and guide the electrode needle directly into the tumor, and through radiofrequency energy to generate high temperature in the local tissue of the lesion, and finally coagulate and inactivate the soft tissue and tumor. The present technology using ablation of electrode needles can produce coagulation necrotic foci up to 5 cm in diameter. For tumor patients with severe cirrhosis estimated to be intolerant to surgery, tumors located in the first or second hepatic hilar estimated to be difficult to operate, combined with serious complications that cannot tolerate surgery, recurrence of hepatocellular carcinoma is inappropriate after surgery or patients are unwilling to undergo surgery, and the number of multiple metastatic hepatocellular carcinoma lesions is less than 3, it is still better to treat with microwave or radiofrequency. Currently, it is reported that for small hepatocellular carcinoma less than 5 cm, the efficacy after ablation is close to that of surgical resection. Postoperative hepatic artery cannulation chemoembolization (TACE) is essential. Patients are routinely treated with 2-4 postoperative transfemoral artery cannulation hepatic angiograms for residual intrahepatic lesions. If there is no sign of recurrence, the patient is given prophylactic chemotherapy. If residual lesions are found, chemoembolization will be given to control the disease. After TACE, CT will be repeated to get a clear picture of the tumor. In case of recurrence, surgical resection, radiofrequency, anhydrous alcohol injection or continued TACE treatment with TCM and bioimmune agents will be given according to different conditions. Combining local treatment such as surgery, radiofrequency or anhydrous alcohol after TACE is an important method to improve the cure rate and survival rate for some patients who cannot be surgically resected. Vascular interventions control the blood supply to the liver tumor and cause ischemic necrosis of the tumor. However, the periphery of the tumor is mainly supplied with blood via portal vein, so it is difficult to completely block all blood supply to the tumor by simple hepatic artery chemoembolization. After the tumor necrosis shrinks, some patients who cannot be resected before surgery become resectable, or can be treated with combined radiofrequency therapy. For small recurrent foci, anhydrous alcohol injection is more economical, convenient and can also achieve better results. Doximet (sorafenib, sorafenib), a multi-kinase inhibitor targeting VEGF and its receptor, is the first targeted therapy drug approved by the FDA for the treatment of metastatic kidney cancer, which can inhibit tumor angiogenesis and anti-tumor cell proliferation, and is a tumor starvation therapy. As a new option for the treatment of advanced hepatocellular carcinoma, Dodgemet can be combined with surgery, intervention, radiofrequency, anhydrous alcohol injection, etc. The results of multiple studies have shown that doxorubicin significantly prolongs the overall survival of patients with advanced hepatocellular carcinoma. Hepatocellular carcinoma patients with a history of hepatitis B or C account for 92.0%, and postoperative recurrence may be related to the replication of hepatitis virus in patients. For patients with hepatitis B major triple-positive, HBV-DNA or HCV-RNA positive, postoperative antiviral therapy such as entecavir, interferon and thymidine, together with traditional Chinese medicine and other treatments to inhibit viral replication, can reduce the recurrence rate of hepatocellular carcinoma. Through these above comprehensive treatments for liver cancer, most patients have been cured of liver cancer, and a few patients with liver cancer have obtained long-term survival with tumor and prolonged survival period. Therefore, most liver cancer patients should still have confidence to overcome the cancer and get a healthy life. We also sincerely wish those liver cancer patients to recover their health as soon as possible.